Eupraxia Pharmaceuticals Inc. is a clinical-stage company headquartered in Victoria, British Columbia, that specializes in targeted, extended-release drug delivery systems. The company utilizes its proprietary polymer-based micro-sphere technology, DiffuSphere™, to augment and transform existing drugs, aiming to improve their safety, tolerability, and efficacy. Its lead clinical candidate, EP-104IAR, has completed Phase 2b trials for the treatment of pain associated with knee osteoarthritis. Additionally, Eupraxia is advancing EP-104GI in Phase 1b/2a trials for eosinophilic esophagitis (EoE), a rare inflammatory gastrointestinal disease. The company's pipeline also explores potential applications in other inflammatory joint indications, oncology, and infectious diseases.
